Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01539083 · BASELINE

Baseline characteristics

Velcade (Bortezomib) Consolidation After Transplant · Source last updated 2025-02-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      254
    units
    Participants
groups
  1. description
    Participants received bortezomib (Velcade) 1.3 milligram per square meter (mg/m\^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m\^2 orally on Days 1, 8, and 15; and dexamethasone 20 milligram (mg) orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 in three 21-day treatment cycles. Participants who completed induction phase entered into the consolidation treatment phase.
    id
    BG000
    title
    Bortezomib + Cyclophosphamide + Dexamethasone (VCD Induction)
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          7.76
          value
          57.8
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          109
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          145
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          207
      title
      Australia
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          17
      title
      China
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          30
      title
      Republic of Korea
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Region of Enrollment
    unit Of Measure
    Participants
population Description
Baseline population was defined as all enrolled participants who received at least 1 non-zero dose of any study drug in the induction phase.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      254
    units
    Participants
groups
  1. description
    Participants received bortezomib (Velcade) 1.3 milligram per square meter (mg/m\^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m\^2 orally on Days 1, 8, and 15; and dexamethasone 20 milligram (mg) orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 in three 21-day treatment cycles. Participants who completed induction phase entered into the consolidation treatment phase.
    id
    BG000
    title
    Bortezomib + Cyclophosphamide + Dexamethasone (VCD Induction)
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          7.76
          value
          57.8
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          109
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          145
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          207
      title
      Australia
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          17
      title
      China
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          30
      title
      Republic of Korea
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Region of Enrollment
    unit Of Measure
    Participants
population Description
Baseline population was defined as all enrolled participants who received at least 1 non-zero dose of any study drug in the induction phase.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice